With the advent of the molecular biology revolution and the human genome project in the 1990s there was a historic shift toward target-based drug development. Target-based drug development, or TDD, relies on prior knowledge of disease mechanisms and targets before development can begin.
We created over 90 point mutations in the STXBP1 gene via CRISPR. A map of these point mutations can be seen above. Clinical variants were selected from the ClinVar database, literature, the Gnomad database, clinical researchers, and the STXBP1 foundation.
June is Alzheimer’s & Brain Awareness Month. We wanted to take a few moments to spotlight some of the awe-inspiring research on Alzheimer’s disease taking
You may or may not know that at InVivo Biosystems, we conduct a lot of grant funded research as well as offering custom models and
New NIH Grant awarded to InVivo Biosystems to address critical needs in precision medicine research using the model of C. elegans. The grant, titled “Functional Assessment of Variants in Organisms of Research (FAVOR) – Profiling Canonical Human Genes and their Variants through Disease Model Phenotyping” in the amount of $350,000 is awared by the Nation Human Genome Research Institute (NHGRI).
Summary: As the zebrafish is increasingly adopted to test drug toxicity, it is critical to systematically assess the parallels between zebrafish, humans and other model systems.
We take a look into why so many zebrafish groups struggle to achieve knock-in transgenesis and what makes knock-ins so difficult.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.